Core Viewpoint - Jingtai Holdings (02228) has seen a significant stock increase, rising over 8% and currently trading at HKD 12.97 with a transaction volume of HKD 1.223 billion, following a collaboration announcement with Hangzhou Baicheng Pharmaceutical [1] Group 1: Collaboration Details - Jingtai Technology has signed a letter of intent with Hangzhou Baicheng Pharmaceutical to utilize its "AI + Robotics" platform for new drug development [1] - Baicheng Pharmaceutical will commission Jingtai Technology to conduct pharmaceutical research and development [1] - The collaboration aims to address unmet clinical needs in various disease areas, including pain, hypersomnia, tumors, autoimmune diseases, and ophthalmology, leveraging Jingtai's AI drug development platform [1] Group 2: Strategic Meetings - On September 24, Jingtai Technology's chairman and CEO visited the headquarters of China Merchants Group to seek strategic collaboration [1] - The visit aimed to enhance communication and cooperation in accelerating new drug development, discovering new materials, and chemical automation [1] - Jingtai Technology looks to leverage this visit to achieve win-win development through resource advantages [1]
晶泰控股再涨超8% 携手百诚医药推进AI新药研发 公司与招商局集团寻求战略协同